Quick answer
All tissue removed during enlarged prostate surgery is sent for pathology examination. Sometimes this examination finds a cancer that no earlier test had shown. In a review of 23 studies, this happened in about 10% of men after TURP and 9% after HoLEP.3 This is incidental cancer, staged as T1a when it involves 5% or less of the tissue, or T1b when it involves more than 5%.1 Many men are managed with active surveillance alone: in a review of enucleation studies, 68.7% were.4
Why all tissue is examined
Enlarged prostate operations remove the benign tissue that squeezes the urethra and leave the capsule. In robotic simple prostatectomy, the tissue comes out in one piece. In HoLEP, the laser frees it and it is broken up inside the bladder before it comes out. In TURP, it comes out in small pieces. In every case, the tissue goes to the pathologist.
Cancer can show up even when a biopsy done before surgery found nothing.7 Breaking up the tissue during HoLEP did not hamper the examination: in a study that compared similar men, cancer was found in 9.7% after HoLEP and 8.3% after open surgery.6
How often cancer is found
| Study | How it was done | Cancer in the tissue |
|---|---|---|
| Guo, 2022 | Review of 23 studies, 94,783 men | TURP, about 10%; HoLEP, 9%; open surgery, 11%3 |
| Cheng, 2022 | Review of 55 studies of endoscopic enucleation | 8%4 |
| Autorino, 2015 | 1,330 robotic and laparoscopic simple prostatectomies | 4%5 |
| Elkoushy, 2015 | 1,242 men treated with HoLEP | 5.64%, of which 77.1% were T1a7 |
In the review of 23 studies, a higher PSA before surgery was the only factor linked to more cancer. Age and prostate size made no difference.3 In the enucleation review, older age, higher PSA and PSA density, and a smaller prostate were associated with more cancer.4
T1a, T1b and the Gleason score
Cancer found during enlarged prostate surgery is staged with the TNM classification:1
| On the report | What it means |
|---|---|
| T1a | Cancer found in 5% or less of the removed tissue1 |
| T1b | Cancer found in more than 5% of the removed tissue1 |
| T1c | Cancer found on a biopsy done, for example, because of a high PSA1 |
The report also gives the Gleason score (for example, 3+3=6) and the matching ISUP grade group, from 1 to 5. The higher the group, the more aggressive the tumor.1 The page on Gleason and ISUP explains the scale.
The report describes only the tissue that came out. The capsule and the outer part of the prostate, the peripheral zone, stay in place and are not examined. So the risk of prostate cancer remains after surgery, and so does the need for follow-up.8
PSA after surgery
PSA is made by prostate tissue. Since surgery removes much of it, PSA drops. In a review of enucleation studies, PSA fell by 82% on average in men without cancer and by 68.2% in men with incidental cancer. The authors expect, after surgery, a PSA below 2 ng/mL and a drop of more than 70%.4
After simple prostatectomy, an American study of 296 men found a first PSA of 0.72 ng/mL in men without cancer and 1.37 ng/mL in men with cancer. The drop was 89% and 78%. A PSA above 2 ng/mL was found in 21% of men with cancer and 4% of men without cancer. PSA also rose faster over time in men with cancer.8
In a French study of 134 men with cancer found at HoLEP, a PSA of 2 ng/mL or more after surgery was the only factor independently linked to the cancer progressing. The risk was highest when that PSA came together with stage T1b.9 The page on PSA explains the test.
What comes after the report
- Going over the reportStage, Gleason score and ISUP grade group, together with the PSA before and after surgery and your overall health.11
- PSA after surgeryThe first value helps single out those at higher risk. In the simple prostatectomy study, it was measured at 3 months.8
- MRIAfter HoLEP, men with cancer can be followed with PSA and MRI.12 See MRI and PI-RADS.
- The choiceActive surveillance or treatment with curative intent, depending on the risk and on what you prefer.2,11
Active surveillance. The European guideline makes active surveillance the standard approach for low-risk cancer.2 In the German HAROW study, 68 men with incidental cancer (54 with T1a and 14 with T1b) stayed on surveillance, with a median follow-up of 7.7 years. None died of the cancer. At 10 years, 98.4% were free of metastases and 61% were still untreated; 33.8% moved on to treatment.10 The page on active surveillance explains the testing schedule.
Radical prostatectomy. For men with a long life expectancy, especially with a less differentiated tumor, radical surgery should be considered.11 It is possible after enlarged prostate surgery, but the operation is more demanding. The European guideline notes that prior TURP can worsen the surgical margin, continence and erections.2 In a review of 10 studies, robotic radical prostatectomy after TURP took about 29 minutes longer, had more complications and more bladder neck reconstruction, and recovery of continence and erections at 1 year was worse. PSA recurrence at 1 year did not differ.13
After HoLEP, the data are still limited. A review of 3 studies, with 63 men, found a longer operation and more bladder neck reconstruction, with no difference in cancer outcomes, continence or erections.14 Another review, of 22 studies, found more complications during surgery, more leakage at the join between the bladder and the urethra and lower continence, with no worsening of erections.15
Radiotherapy. The European guideline accepts brachytherapy after TURP, without an increase in urinary side effects, as long as the TURP left enough tissue and at least 3 months pass between the two.2 A review of older studies, on the other hand, found more urinary side effects when radiotherapy follows TURP.16 After HoLEP, continence was better with radiotherapy than with radical surgery.15
When to worry less and when to look further
| Item | Favors monitoring | Calls for more investigation |
|---|---|---|
| Stage | T1a | T1b, especially with a high PSA9 |
| Grade | Well differentiated tumor | Less differentiated tumor11 |
| PSA after surgery | Low and stable | 2 ng/mL or more, or rising over time8,9 |
| Life expectancy | Limited | Long11 |
In the HAROW study, a PSA of 1.0 ng/mL or more after surgery and a PSA density of 0.2 or more were associated with moving from surveillance to treatment.10 None of these signs decides on its own: they are weighed together with the report and your overall health.
How I approach it
I treat enlarged prostate and prostate cancer. For my PhD at the University of São Paulo Medical School, I studied radical prostatectomy slides with an artificial intelligence model compared against a uropathologist. At the consultation, I go through the report with you and we put it together with the PSA after surgery. When the MRI shows PI-RADS 3 or higher, in my practice I always recommend a biopsy, which I perform under sedation. I present active surveillance and treatment as options, and we decide together. If you were operated on by another surgeon and want a second opinion, the consultation can be online, in English, with the report and tests sent in advance.
When to see a urologist
- If the report from your prostate surgery showed cancer, even T1a
- If you do not know the result of the examination of the removed tissue
- If your PSA rises after surgery
- If you want to compare active surveillance with treatment in your case
Frequently asked questions
What is incidental prostate cancer?+
It is cancer found by chance when prostate tissue removed for another reason is examined, usually during enlarged prostate surgery. Under the TNM classification, it is T1a when it involves 5% or less of the tissue and T1b when it involves more than 5%.1
How often is cancer found after enlarged prostate surgery?+
In a review of 23 studies, cancer was found in about 10% of men after TURP, 9% after HoLEP and 11% after open surgery.3 In a series of 1,330 robotic and laparoscopic simple prostatectomies, it was found in 4%.5
What is the difference between T1a and T1b?+
In T1a, the cancer involves 5% or less of the removed tissue; in T1b, more than 5%.1 In a series of men treated with HoLEP, those with T1b and a PSA of 2 ng/mL or more after surgery had the highest risk of the cancer progressing.9
Do I need treatment for cancer found during prostate surgery?+
Not always. In a German study of 68 men on active surveillance after the finding, none died of the cancer over about 8 years of follow-up, and 61% were still untreated at 10 years.10 The decision takes into account the stage, the Gleason score, the PSA after surgery and life expectancy.11
Why does PSA drop after enlarged prostate surgery?+
Because much of the tissue that makes PSA has been removed. In a review of enucleation studies, PSA fell by 82% on average in men without cancer. After surgery, a PSA below 2 ng/mL and a drop of more than 70% are expected.4
Can I still have a radical prostatectomy after TURP or HoLEP?+
Yes, but the operation is more demanding. In a review of 10 studies, robotic radical prostatectomy after TURP took about 29 minutes longer and had more complications, and recovery of continence and erections at 1 year was worse.13 After HoLEP, the studies are still few and small.14,15
Who treats prostate cancer found after enlarged prostate surgery in São Paulo?+
I am Dr. Petronio Melo, a urologist and robotic surgeon in São Paulo, Brazil, CRM-SP 157.598 and RQE 70.275. I treat enlarged prostate and prostate cancer, and I have performed more than 1,500 robotic and laparoscopic surgeries, more than 500 of them robotic. For my PhD at the University of São Paulo Medical School, I studied radical prostatectomy slides with artificial intelligence. When the MRI shows PI-RADS 3 or higher, I recommend a biopsy, always under sedation. My office is in Vila Mariana, and the first consultation can be in person or online, in English.
References
- EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: classification and staging systems. European Association of Urology; 2026. EAU
- EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: treatment. European Association of Urology; 2026. EAU
- Guo Z, He J, Huang L, et al. Prevalence and risk factors of incidental prostate cancer in certain surgeries for benign prostatic hyperplasia: A systematic review and meta-analysis. Int Braz J Urol. 2022;48(6):915-929. PubMed
- Cheng BK, Castellani D, Chan IS, et al. Incidence, predictive factors and oncological outcomes of incidental prostate cancer after endoscopic enucleation of the prostate: a systematic review and meta-analysis. World J Urol. 2022;40(1):87-101. PubMed
- Autorino R, Zargar H, Mariano MB, et al. Perioperative Outcomes of Robotic and Laparoscopic Simple Prostatectomy: A European-American Multi-institutional Analysis. Eur Urol. 2015;68(1):86-94. PubMed
- Rosenhammer B, Lausenmeyer EM, Mayr R, et al. Holmium Laser Enucleation of the Prostate Provides Similar Incidental Prostate Cancer Detection Rates as Open Prostatectomy: A Matched Pair Analysis. Urol Int. 2018;101(4):382-386. PubMed
- Elkoushy MA, Elshal AM, Elhilali MM. Incidental Prostate Cancer Diagnosis During Holmium Laser Enucleation: Assessment of Predictors, Survival, and Disease Progression. Urology. 2015;86(3):552-557. PubMed
- Livingston AJ, Segal D, Attia S, et al. Multi-institutional evaluation of prostate specific antigen dynamics after simple prostatectomy. World J Urol. 2026;44(1):243. PubMed
- Klein C, Marquette T, Capon G, et al. Incidental prostate cancer after holmium laser enucleation of the prostate: incidence and predictive factors for clinical progression. Int J Clin Oncol. 2022;27(6):1077-1083. PubMed
- Herden J, Schwarte A, Boedefeld EA, et al. Active Surveillance for Incidental (cT1a/b) Prostate Cancer: Long-Term Outcomes of the Prospective Noninterventional HAROW Study. Urol Int. 2021;105(5-6):428-435. PubMed
- Capitanio U. Contemporary management of patients with T1a and T1b prostate cancer. Curr Opin Urol. 2011;21(3):252-256. PubMed
- Hutchison D, Peabody H, Kuperus JM, et al. Management of prostate cancer after holmium laser enucleation of the prostate. Urol Oncol. 2021;39(5):297.e1-297.e8. PubMed
- Gu L, Li Y, Li X, et al. Does previous transurethral resection of the prostate negatively influence subsequent robotic-assisted radical prostatectomy in men diagnosed with prostate cancer? A systematic review and meta-analysis. J Robot Surg. 2023;17(4):1299-1307. PubMed
- Ditonno F, Ronca M, Pettenuzzo G, et al. Impact of Prior Holmium Laser Enucleation of the Prostate on Robot-Assisted Radical Prostatectomy Outcomes: A Systematic Review and Meta-Analysis of Comparative Studies. J Endourol. 2026;40(4):488-497. PubMed
- Artiles Medina A, Tagalos Muñoz A, Domínguez Gutiérrez A, et al. Outcomes of Active Treatment for Localised Prostate Cancer After Holmium Laser Enucleation of the Prostate: A Systematic Review and Meta-analysis. Eur Urol Open Sci. 2025;79:111-127. PubMed
- Ishiyama H, Hirayama T, Jhaveri P, et al. Is there an increase in genitourinary toxicity in patients treated with transurethral resection of the prostate and radiotherapy? A systematic review. Am J Clin Oncol. 2014;37(3):297-304. PubMed
Would you like to talk about your case?
In the consultation, I go over your tests and your priorities.
Book a consultation
